Prognostic factors analysis of surgical resection after conversion therapy for isolated pleural metastatic lung cancer: a retrospective analysis.
Аннотация
OBJECTIVE
To explore the efficacy and prognostic factors of surgical resection in patients with non-small cell lung cancer (NSCLC) and isolated pleural metastasis (M1a) after receiving individualized conversion therapy.
METHODS
This retrospective study included 167 patients with non-small cell lung carcinoma (NSCLC) and isolated pleural metastasis (M1a) admitted to Beijing Chest Hospital, Capital Medical University, from January 2019 to December 2023. Based on genotyping results, targeted therapy or chemo-immunotherapy regimens were administered. After conversion therapy, a multidisciplinary team (MDT) assessed surgical feasibility. The primary endpoint following comprehensive treatment was overall survival (OS) and progression-free survival (PFS), secondary endpoints included Objective response rate (ORR) and disease control rate (DCR); incidence of postoperative complications and Recurrence status. Survival probabilities were estimated using the Kaplan-Meier method, and independent prognostic factors were identified using the Cox proportional hazards regression model.
RESULTS
The median follow-up for all patients was 28.5 months. In total, 167 patients (82.26%) underwent curative or cytoreductive surgery. The median OS was 22.6 months (95%CI: 18.4-26.8), and the median PFS was 12.4 months (95% CI: 9.2-15.6). The 1-year and 2-year survival rates were 89.7 and 42.1%, respectively. Multivariate analysis revealed that squamous cell carcinoma (vs. adenocarcinoma, HR = 1.68, p = 0.012), driver gene negativity (HR = 1.61, p = 0.024), SD as the response to conversion therapy (vs.PR/CR, HR = 1.82, p = 0.006), N2 lymph node metastasis (HR = 1.85, p = 0.003), and non-R0 resection (HR = 2.08, p = 0.001) were independent risk factors for OS. The postoperative complication rate was 12.57% (21/167); complications of Clavien-Dindo grade ≥3 occurred in 28.57% (6/21) of patients. Perioperative death occurred in one patient.
CONCLUSION
Surgical resection after effective conversion therapy significantly improves long-term survival in patients with isolated pleural metastatic lung cancer. Histological subtype, molecular characteristics, and completeness of resection are key prognostic indicators. Clinically, surgical intervention should prioritize patients who demonstrate a favorable response to conversion therapy, achieve R0 resection, and harbor driver gene mutations.
CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/, identifier ChiCTR2200056791.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.